Results India
Mankind Pharma reported a 37.7% year-on-year rise in consolidated net profit (PAT) to ₹716 crore for Q2 FY27, driven by strong domestic demand for chronic therapies and international revenue growth, with its stock closing 3.38% higher at ₹2,302 per share.
Mankind Pharma's Q2 FY27 results showed a 37.7% year-on-year (Y-o-Y) increase in PAT to ₹716 crore, fueled by robust domestic chronic therapies and a 33% Y-o-Y jump in international revenue to ₹2,061 crore. Domestic revenue grew 14.8% to ₹3,657 crore, contributing 86% of total revenue, while revenue from operations rose 17.3% to ₹4,338 crore. The stock surged 3.38% on the BSE following the results.
The company’s focus on chronic therapies, particularly cardiac and anti-diabetes drugs, drove growth, with domestic chronic therapies accounting for significant revenue. However, the OTC consumer healthcare segment grew only 1.2% Y-o-Y, impacted by industry-wide slowdowns and regional challenges in the east and south. Mankind Pharma’s acquisition of Armed Cell Therapeutics positions it to enter next-generation CAR-T therapies, enhancing its R&D capabilities for future growth.
The results highlight Mankind Pharma’s reliance on chronic therapies and international expansion for profitability. While the OTC segment’s muted growth raises concerns about market penetration, the strategic move into CAR-T therapies signals a long-term play in advanced oncology treatments. Competitors in chronic disease and CAR-T markets now face intensified competition from Mankind Pharma’s expanded portfolio.
Investors and shareholders benefit from the stock’s rise and improved margins, while domestic healthcare providers and patients gain access to more chronic treatments. Risks remain in the OTC segment, but the acquisition of Armed Cell Therapeutics offers opportunities to strengthen R&D and future growth prospects.
Mankind Pharma's stock closed 3.38% higher at ₹2,302 per share on BSE following the results announcement.
Mankind Pharma’s strong PAT growth reflects its dominance in chronic therapies and international markets, but the OTC segment’s underperformance highlights potential vulnerabilities. The acquisition of Armed Cell Therapeutics could shape its future R&D trajectory.
Topics: Pharmaceuticals, India, Stock Market, Healthcare, R&D, Chronic Diseases, CAR-T Therapies, Revenue Growth
#MankindPharma #PharmaGrowth #ChronicTherapies #CARTTreatment #StockPerformance #IndiaPharma #RNDExpansion
Source: Business Standard
Post a Comment
Post a Comment